Lv11
44 积分 2023-07-03 加入
CircATXN7 regulates the proliferation and invasion of esophageal cancer cells through miR-4319/NLRC5
1天前
已完结
Rechallenging with anti-PD-1 therapy in advanced renal cell carcinoma
3天前
已完结
Rechallenge with immune checkpoint inhibitors for advanced esophageal squamous cell carcinoma
3天前
已完结
Radiotherapy plus camrelizumab and irinotecan for oligometastatic esophageal squamous cell carcinoma patients after first-line immunotherapy plus chemotherapy failure: An open-label, single-arm, phase II trial
3天前
已完结
Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach?
4天前
已完结
Efficacy and safety of camrelizumab plus apatinib in patients with advanced esophageal squamous cell carcinoma previously treated with immune checkpoint inhibitors (CAP 02 Re-challenge): a single-arm, phase II study
7天前
已完结
Paclitaxel/Ramucirumab vs. Paclitaxel in 2nd-line therapy of advanced esophageal squamous cell carcinoma: Randomized Phase II IKF-AIO-RAMOS Trial
7天前
已关闭
PD-1/PD-L1 Inhibitors in Combination with Chemo or as Monotherapy vs. Chemotherapy Alone in Advanced, Unresectable HER2-Negative Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: A Meta-Analysis
7天前
已完结
Paclitaxel/Ramucirumab vs. Paclitaxel in 2nd-line therapy of advanced esophageal squamous cell carcinoma: Randomized Phase II IKF-AIO-RAMOS Trial
7天前
已关闭
Paclitaxel/Ramucirumab vs. Paclitaxel in 2nd-line therapy of advanced esophageal squamous cell carcinoma: Randomized Phase II IKF-AIO-RAMOS Trial
7天前
已关闭
皖公网安备34019202002308
